Jessica L Barnhill, Isabel J Roth, Vanessa E Miller, John M Baratta, Aisha Chilcoat, Bethany M Kavalakatt, Malik K Tiedt, Karla L Thompson, Paula Gardiner
{"title":"虚拟综合医疗小组访问中长期COVID患者报告结果措施的试点观察研究","authors":"Jessica L Barnhill, Isabel J Roth, Vanessa E Miller, John M Baratta, Aisha Chilcoat, Bethany M Kavalakatt, Malik K Tiedt, Karla L Thompson, Paula Gardiner","doi":"10.1177/27536130231174236","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Long COVID is a common, debilitating post-infectious illness for which effective management is unknown. Integrative Medical Group Visits (IMGV) are effective interventions for chronic conditions and could benefit Long COVID patients. More information is needed regarding existing patient reported outcome measures (PROMs) to evaluate efficacy of IMGV for Long COVID.</p><p><strong>Objective: </strong>This study assessed the feasibility of specific PROMS to evaluate IMGVs for Long COVID. Findings will inform future efficacy trials.</p><p><strong>Methods: </strong>The Perceived Stress Scale (PSS-10), General Anxiety Disorder two-question tool (GAD-2), Fibromyalgia Symptom Severity scale (SSS), and Measure Yourself Medical Outcome Profile (MYMOP®) were collected pre- and post-group by teleconferencing platform or telephone and compared using paired t-tests. Patients were recruited from a Long COVID specialty clinic where they participated in 2-hour - 8 weekly IMGV sessions online.</p><p><strong>Results: </strong>Twenty-seven participants enrolled and completed pre-group surveys. Fourteen participants were reachable by phone post-group and completed all pre and post PROMs (78.6% female, 71.4% non-Hispanic White, mean age 49). MYMOP® primary symptomatology was fatigue, shortness of breath and \"brain fog\". Symptoms decreased in interference when compared to pre-group levels (mean difference -1.3 [95% CI-2.2, -.5]). PSS scores decreased (-3.4 [95% CI -5.8, -1.1]), and GAD-2 mean difference was -1.43 (95% CI -3.12, .26). There were no changes in SSS scores of fatigue (-.21 [95% CI -.68,0.25]), waking unrefreshed (.00 [95%CI -.32, -.32]), or trouble thinking (-.21 [95% CI -.78,0.35]).</p><p><strong>Conclusion: </strong>All PROMs were feasible to administer via teleconferencing platform or telephone. The PSS, GAD-2 and MYMOP® are promising PROMs to track Long COVID symptomatology among IMGV participants. The SSS, while feasible to administer, did not change compared to baseline. Larger, controlled studies are needed to determine the efficacy of virtual IMGVs to address the needs of this large and growing population.</p>","PeriodicalId":73159,"journal":{"name":"Global advances in integrative medicine and health","volume":"12 ","pages":"27536130231174236"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/17/10.1177_27536130231174236.PMC10186579.pdf","citationCount":"0","resultStr":"{\"title\":\"Pilot Observational Study of Patient Reported Outcome Measures for Long COVID Patients in Virtual Integrative Medical Group Visits.\",\"authors\":\"Jessica L Barnhill, Isabel J Roth, Vanessa E Miller, John M Baratta, Aisha Chilcoat, Bethany M Kavalakatt, Malik K Tiedt, Karla L Thompson, Paula Gardiner\",\"doi\":\"10.1177/27536130231174236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Long COVID is a common, debilitating post-infectious illness for which effective management is unknown. Integrative Medical Group Visits (IMGV) are effective interventions for chronic conditions and could benefit Long COVID patients. More information is needed regarding existing patient reported outcome measures (PROMs) to evaluate efficacy of IMGV for Long COVID.</p><p><strong>Objective: </strong>This study assessed the feasibility of specific PROMS to evaluate IMGVs for Long COVID. Findings will inform future efficacy trials.</p><p><strong>Methods: </strong>The Perceived Stress Scale (PSS-10), General Anxiety Disorder two-question tool (GAD-2), Fibromyalgia Symptom Severity scale (SSS), and Measure Yourself Medical Outcome Profile (MYMOP®) were collected pre- and post-group by teleconferencing platform or telephone and compared using paired t-tests. Patients were recruited from a Long COVID specialty clinic where they participated in 2-hour - 8 weekly IMGV sessions online.</p><p><strong>Results: </strong>Twenty-seven participants enrolled and completed pre-group surveys. Fourteen participants were reachable by phone post-group and completed all pre and post PROMs (78.6% female, 71.4% non-Hispanic White, mean age 49). MYMOP® primary symptomatology was fatigue, shortness of breath and \\\"brain fog\\\". Symptoms decreased in interference when compared to pre-group levels (mean difference -1.3 [95% CI-2.2, -.5]). PSS scores decreased (-3.4 [95% CI -5.8, -1.1]), and GAD-2 mean difference was -1.43 (95% CI -3.12, .26). There were no changes in SSS scores of fatigue (-.21 [95% CI -.68,0.25]), waking unrefreshed (.00 [95%CI -.32, -.32]), or trouble thinking (-.21 [95% CI -.78,0.35]).</p><p><strong>Conclusion: </strong>All PROMs were feasible to administer via teleconferencing platform or telephone. The PSS, GAD-2 and MYMOP® are promising PROMs to track Long COVID symptomatology among IMGV participants. The SSS, while feasible to administer, did not change compared to baseline. Larger, controlled studies are needed to determine the efficacy of virtual IMGVs to address the needs of this large and growing population.</p>\",\"PeriodicalId\":73159,\"journal\":{\"name\":\"Global advances in integrative medicine and health\",\"volume\":\"12 \",\"pages\":\"27536130231174236\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/17/10.1177_27536130231174236.PMC10186579.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global advances in integrative medicine and health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/27536130231174236\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global advances in integrative medicine and health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/27536130231174236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:长冠肺炎是一种常见的、使人衰弱的感染后疾病，目前尚无有效的治疗方法。综合医疗小组访问(IMGV)是对慢性疾病的有效干预措施，可以使长期COVID患者受益。需要更多关于现有患者报告的结果测量(PROMs)的信息来评估IMGV对长期COVID的疗效。目的:探讨特异性PROMS评价长冠期IMGVs的可行性。研究结果将为未来的疗效试验提供信息。方法:通过远程会议平台或电话收集组前和组后感知压力量表(PSS-10)、一般性焦虑障碍双题工具(GAD-2)、纤维肌痛症状严重程度量表(SSS)和自我医疗结局量表(MYMOP®)，采用配对t检验进行比较。患者从一家Long COVID专科诊所招募，在那里他们参加了每周2小时至8小时的在线IMGV会议。结果:27名参与者入组并完成组前调查。14名参与者通过电话联系，完成了所有的prom前后(78.6%为女性，71.4%为非西班牙裔白人，平均年龄49岁)。MYMOP®的主要症状是疲劳、呼吸短促和“脑雾”。与组前水平相比，干扰症状减轻(平均差值-1.3 [95% CI-2.2， - 0.5])。PSS评分下降(-3.4 [95% CI -5.8， -1.1])， GAD-2平均差异为-1.43 (95% CI -3.12, 0.26)。疲劳SSS评分(-)无明显变化。21 [95% CI - 0.68,0.25])，醒后不清醒(。[95%ci -。][32， -.32])，或者思考困难(-。[95% ci - 0.78,0.35])。结论:通过远程会议平台或电话进行管理是可行的。PSS、GAD-2和MYMOP®是有希望跟踪IMGV参与者的长期COVID症状的PROMs。SSS虽然可行，但与基线相比没有变化。需要更大规模的对照研究来确定虚拟imgv的功效，以满足这一庞大且不断增长的人口的需求。
Pilot Observational Study of Patient Reported Outcome Measures for Long COVID Patients in Virtual Integrative Medical Group Visits.
Background: Long COVID is a common, debilitating post-infectious illness for which effective management is unknown. Integrative Medical Group Visits (IMGV) are effective interventions for chronic conditions and could benefit Long COVID patients. More information is needed regarding existing patient reported outcome measures (PROMs) to evaluate efficacy of IMGV for Long COVID.
Objective: This study assessed the feasibility of specific PROMS to evaluate IMGVs for Long COVID. Findings will inform future efficacy trials.
Methods: The Perceived Stress Scale (PSS-10), General Anxiety Disorder two-question tool (GAD-2), Fibromyalgia Symptom Severity scale (SSS), and Measure Yourself Medical Outcome Profile (MYMOP®) were collected pre- and post-group by teleconferencing platform or telephone and compared using paired t-tests. Patients were recruited from a Long COVID specialty clinic where they participated in 2-hour - 8 weekly IMGV sessions online.
Results: Twenty-seven participants enrolled and completed pre-group surveys. Fourteen participants were reachable by phone post-group and completed all pre and post PROMs (78.6% female, 71.4% non-Hispanic White, mean age 49). MYMOP® primary symptomatology was fatigue, shortness of breath and "brain fog". Symptoms decreased in interference when compared to pre-group levels (mean difference -1.3 [95% CI-2.2, -.5]). PSS scores decreased (-3.4 [95% CI -5.8, -1.1]), and GAD-2 mean difference was -1.43 (95% CI -3.12, .26). There were no changes in SSS scores of fatigue (-.21 [95% CI -.68,0.25]), waking unrefreshed (.00 [95%CI -.32, -.32]), or trouble thinking (-.21 [95% CI -.78,0.35]).
Conclusion: All PROMs were feasible to administer via teleconferencing platform or telephone. The PSS, GAD-2 and MYMOP® are promising PROMs to track Long COVID symptomatology among IMGV participants. The SSS, while feasible to administer, did not change compared to baseline. Larger, controlled studies are needed to determine the efficacy of virtual IMGVs to address the needs of this large and growing population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
